Home > Science & Innovation > Our approach to clinical development
Advancing clinical research
We are committed to advancing specialty care and treatment of rare diseases, with a strong focus on the following areas
Our pipeline in Gastroenterology and Hepatology targets areas of high unmet need, including:
- Primary biliary cholangitis (PBC) – a chronic autoimmune liver disease causing progressive destruction of the bile ducts
- Cholestatic pruritus in adult PBC patients – a severe and often debilitating itch caused by impaired bile flow
In immunology, we focus on developing innovative treatments for immune-mediated diseases, including:
- Axial Spondyloarthritis – a chronic inflammatory disease causing painful stiffness of the spine and sacroiliac joints
- Polyarticular Juvenile Idiopathic Arthritis – the most common chronic autoimmune arthritis in children, leading to joint inflammation and pain
- Systemic Juvenile Idiopathic Arthritis – a severe childhood inflammatory disease characterised by arthritis with systemic features such as recurrent high fevers and rash
- Pediatric Ulcerative Colitis – a disease characterised by remitting and relapsing inflammation of the large intestine in children, negatively affecting growth, development, psychosocial function, and overall well-being.
We are exploring opportunities in infectious diseases, including Herpes Simplex Virus Encephalitis – a life‑threatening viral infection causing acute inflammation of the brain.
Transparency, access and collaboration
Driving scientific transparency
Scientific transparencyExpanded access at Alfasigma
Expanded accessExternal sponsored research
Sponsored researchOur development programmes have the potential to deliver meaningful breakthroughs for patients, positioning us at the forefront of innovation. We continue to invest in strengthening and expanding our pipeline to serve patients worldwide